Pepscan Holding NV

Rebranding aligns core Biosynth Group members across Complex Chemical and Peptide Manufacturing Services and Catalog Business. STAAD, Switzerland--(BUSINESS WIRE)-- Biosynth Carbosynth, vivitide and Pepscan are pleased to announce today their rebranding to Biosynth to match their parent group and the launch of their site at . Biosynth is a global supplier of critical products and services to the life sciences industry, across the areas of complex chemicals, quality peptides and key biological reagents. In combination with their research product portfolio of more than 600K catalog products across all three areas, Biosynth partners with customers from their first idea to finished product, across research, development and commercial supply of key materials. The new branding evokes the unique combinations that Biosynth offers, where Products meet Services and where Chemistry meets Biology, Biosynth is at “The Edge of Innovation.” Dr. Urs Spitz, CEO and President of Biosynth, said, “We are thrilled to be unveiling our new Biosynth brand today, and to be formally integrating Pepscan and vivitide into the organization. We have long been the go to provider of complex chemicals across carbohydrates, nucleoside, enzyme substrates and beyond, and now have such breadth across peptides. We knew it was the right time to bring us all together so our customers can go to one place for all their needs.” Editor’s notes About Biosynth Biosynth is a supplier of critical materials, securing life sciences supply chains with global research, manufacturing and distribution facilities. Supplying the pharmaceutical, life science and diagnostic sectors; where Chemistry meets Biology, Products meet Services and Innovation meets Quality, Biosynth is at the Edge of Innovation. With an unrivaled research product portfolio of over half a million products and end-to-end manufacturing services, Biosynth’s expertise and capability runs across Complex Chemicals, Peptides and Key Biologics all from one trusted partner. Headquartered in Staad, Switzerland, Biosynth is owned by KKR, Ampersand Capital Partners and management. Find out more about Biosynth at . Other members of the Biosynth group are unaffected by the rebranding at this time. View source version on businesswire.com: Contacts Alto Marketing: Max Kingston - E: maxk@alto-marketing.com; T: +44 7342 385261 Biosynth: Aimee Cossins – E: marketing@biosynth.com, T: +44 7984 525560 Source: Biosynth Carbosynth View this news release online at:

The CDMO WuXi STA has been rapidly expanding over the past year, and its next opening will expand its offering in the peptide sector. WuXi has opened two new large-scale oligonucleotide and peptide manufacturing facilities at its campus in Changzhou, China, according to the company. However, the financial and employment details have not been disclosed to Endpoints News. The new 30,000 square-foot facility for oligonucleotide development and manufacturing contains four oligonucleotide production lines and more than 20 small- to mid-scale production lines that should increase the overall manufacturing capacity of a single synthesis run from 1.9 mol to 6.0 mol. For peptides, WuXi has constructed a new 22,000 square-foot peptide plant that features three new production lines with reactors that can accommodate up to 1,000 L, increasing the company’s overall solid-phase peptide synthesis reactor volume to 6,490 L. “WuXi STA is committed to enabling partners by enhancing our new modality CRDMO platform’s capacity and capability to expedite the development and commercialization of more innovative therapies to benefit patients worldwide,” said Minzhang Chen, the Co-CEO of WuXi AppTec and WuXi STA. The new facility is a part of WuXi STA’s CRDMO platform for supporting not only oligonucleotides and peptides, but novel monomers and linkers, and complex conjugates, from early discovery to development and commercial production. WuXi recently opened another high-potency API (HPAPI) plant at its Changzhou site located in Jiangsu, China. The new plant is designed to meet the growing demand for high-potency APIs. Last year the company also established facilities in Europe and the US. Swiss manufacturer Biosynth Carbosynth has netted another acquisition. The company announced on Monday that it has acquired Pepscan, a Dutch provider of peptide-based products and services. The financial terms of the deal were not disclosed, but the two companies will form Biosynth’s new peptide division. The new division will offer peptides to the pharma and biotech industries along with the diagnostics and cosmetics industries. “This allows us to continue to simplify the supply chains for our customers across life sciences, pharma and diagnostics, so they deal with one organization for all of their needs. Pepscan is known for its scientific knowledge and expertise and has a complementary set of manufacturing to those we have already, including GMP capabilities, so it was a perfect fit,” said Biosynth CEO and president Urs Spitz. Biosynth has been on the move recently as the company acquired Irish-based Aalto Bio Reagents, a developer and provider of biological materials to the in-vitro diagnostic (IVD) and vaccine development industry. As Switzerland continues to see both international and home-grown companies building out spaces, two more companies are getting in on the action. KBI Biopharma and Selexis SA have opened a 94,000-square-foot facility that is designed meet the high demand for biopharmaceutical drug development and manufacturing in Europe. According to KBI, the facility will support an integrated, end-to-end process of Selexis’ cell line development services along with KBI’s CDMO services. “KBI and Selexis have a long history of success together, our collaboration has accelerated more than 60 drug development programs in Europe and worldwide. Integrating Selexis’ world-renowned CLD services with KBI’s process development innovation and excellence, as well as clinical and commercial manufacturing experience provides our clients with seamless, cost-effective, and reliable development and manufacturing for their products,” said KBI CEO Mark Womack. According to KBI, the facility will house new laboratories to support Selexis’ cell line manufacturing and KBI’s process development and cGMP manufacturing. The facility will also feature quality control with a suite for testing laboratories and cGMP single-use manufacturing trains. The expansion will also generate over 300 new jobs in development, operations and quality assurance.

LELYSTAD, the Netherlands, June 28, 2022 /PRNewswire/ -- Pepscan, the all-in-one peptide service provider, is excited to announce that it will supply personalized peptide pools for six patients in a phase I trial led by Mayo Clinic principal investigator Yanyan Lou, M.D., Ph.D., in collaboration with Keith L. Knutson, Ph.D. The trial tests the safety and tolerability of an experimental personalized peptide vaccine when given in combination with pembrolizumab in treating patients with a wide range of advanced solid tumors and tumors that have spread to other places in the body (metastases). The vaccine is designed to target certain proteins (neoantigens) on individuals' tumor cells. Combination immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer and thereby interfere with the ability of the tumor cells to grow and spread. "Mayo Clinic is recognized as one of the best hospital groups in the US and we are excited to provide the peptide pools for their investigational phase I study. Supplying top researchers and clinicians worldwide to turn their ideas into better treatment outcomes for patients is what we aim for at Pepscan." says Hans de Backer, CEO of Pepscan. The primary objective of the study "Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors" is to evaluate the safety, side effects, optimal dosages and risks/benefits of a personalized neoantigen peptide vaccine in combination with pembrolizumab in advanced solid cancers. Pepscan will manufacture up to 20 unique peptides and combine them into peptide pools, making up the active pharmaceutical ingredient (API) of the vaccine. All within only 5 weeks to shipment (under quarantine). Besides the manufacturing, Pepscan also supported Mayo Clinic with the CMC (chemistry, manufacturing and control) report, which was submitted as part of Mayo's Investigational New Drug (IND) Application and has been approved by the FDA. Manufacturing personalized peptides for neoantigen vaccines requires a very specific set of process development and manufacturing skills, facilities and analytical methods. With 25 years of experience in mastering peptides and flexible manufacturing capabilities, Pepscan reliably delivers individual or pooled peptide sets that fit its customers' timelines. Contact information: Evert van Dijk, CCO +31 320 225 300 [email protected] About Pepscan Pepscan is an all-in-one partner in peptides, building on 25 years of experience in advancing and applying peptide expertise to facilitate customers in the development and production of peptides. At its end-to-end facility in Lelystad, the Netherlands, Pepscan offers a range of patented technologies, phage display capabilities, a lead-optimization array platform, and production facilities for R&D- to GMP-grade peptides, including neoantigen libraries and vaccines. Among its patents is the CLIPS™ technology, which locks peptides into active conformations. With its epitope mapping service platform, Pepscan also supports biotech companies in developing their antibody pipelines. The underlying protein mimicry platform delivers binding insights, even in cases where other technologies fall short. Preparing neoantigen peptides demands the highest level of care and reliability in terms of tailoring to the patient's specifications and timely delivery for their care. Owing to our thorough expertise in peptide chemistry and our role as critical partner in multiple clinical trial projects, Pepscan knows what it takes to be a world-class partner in this field. SOURCE Pepscan